Overview

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This Phase II randomized study is to determine the efficacy and toxicity of toripalimab plus neoadjuvant chemotherapy combined with chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Capecitabine
Nedaplatin
Paclitaxel